Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis
Conditions
Interventions
Interferon beta-1a
Ocrelizumab-matching placebo
+2 more
Locations
142
United States
21st Century Neurology
Phoenix, Arizona, United States
Mercy Medical Group
Carmichael, California, United States
Scripps Clinic
La Jolla, California, United States
MS Center of California
Laguna Hills, California, United States
Southern California Permanente Medical Group
Los Angeles, California, United States
Neuro-Therapeutics Inc.
Pasadena, California, United States
Start Date
August 31, 2011
Primary Completion Date
April 2, 2015
Completion Date
December 31, 2022
Last Updated
March 4, 2024
NCT05344469
NCT07426991
NCT06433752
NCT06617793
NCT04047628
NCT06486779
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions